Nektar (NKTR) Chief R&D Officer Jonathan Zalevsky Sells Shares

What Happened
Jonathan Zalevsky, Chief Research & Development Officer of Nektar Therapeutics (NKTR), sold 186 shares on August 18, 2026. The weighted-average sale price was $71.98, generating proceeds of approximately $13,388. The filing indicates this sale was to satisfy tax withholding obligations tied to the vesting of RSUs and was not a discretionary trade.

Key Details

• Transaction date: 2026-08-18 (filed with the SEC on 2026-08-20 — timely filing).
• Transaction type: Sale (reported as open market/private sale); footnote says sale was to cover tax withholding for RSU vesting.
• Shares sold: 186; weighted-average price: $71.98; total proceeds reported: $13,388.
• Price range: trades executed across $71.78 to $72.49; weighted average reported (footnote offers to provide per-trade details on request).
• Shares owned after transaction: Not disclosed in the filing.

Context
This was a withholding sale tied to RSU vesting (tax-related), which is generally routine and does not necessarily signal a change in the insider’s view of the company. The filing’s footnote clarifies the sale was to cover required tax withholding and not a discretionary sale.